Breast Cancer Treatment
Alliance Foundation Trials LLC supports clinical research in hormone receptor-positive and HER2-positive breast cancer, with interest in both metastatic disease and early breast cancer. Its studies focus on treatment strategies that combine endocrine therapy with targeted agents to improve disease control and long-term outcomes.
- Metastatic breast cancer
- HR+/HER2+ disease
- HR+/HER2- early breast cancer
- Endocrine-based therapy
Research activity in this area centers on treatment approaches for patients with limited prior therapy and on adjuvant strategies aimed at reducing recurrence risk.
Targeted Oncology and Cell Cycle Inhibition
The sponsor funds trials examining palbociclib in combination with established breast cancer regimens, reflecting a strong therapeutic interest in CDK4/6 inhibition within breast oncology. These studies address both advanced and adjuvant settings, with attention to how targeted therapy integrates with anti-HER2 therapy and endocrine treatment.
- Palbociclib-based combinations
- CDK4/6 inhibition
- Anti-HER2 therapy
- Combination oncology regimens
This area highlights interest in precision approaches for improving progression control and invasive disease-free outcomes in breast cancer.
Cancer Prevention in BRCA1 Carriers
Alliance Foundation Trials LLC also supports prevention-focused research for women with a germline BRCA1 mutation, with the aim of lowering the risk of developing breast cancer. The sponsor’s work in this domain includes evaluation of preventive interventions for both invasive cancer and ductal carcinoma in situ.
- BRCA1 germline mutation
- Breast cancer prevention
- High-risk women
- Invasive and non-invasive breast lesions
These studies reflect a therapeutic interest in risk reduction for genetically predisposed populations.
Bone-Related Preventive Oncology
The sponsor’s portfolio includes investigation of denosumab in a prevention setting for women at elevated hereditary risk of breast cancer. This connects oncology research with bone-targeted therapy and preventive care, extending interest beyond treatment of established malignancy.
- Denosumab
- Bone-targeted therapy
- Hereditary cancer risk
- Cancer interception
Clinical activity in this area focuses on strategies that may alter cancer development in genetically susceptible women.
